Finally, since most KRAS‐G12C patients in our study had advanced disease stages (stages III and IV), as predictive CRC targeted panels are typically conducted for metastatic cases,8, 25 the true frequency of MAP in all CRC stages may be underestimated. This evidence concerns the gene KRAS and colorectal carcinoma.